Clinical Outcomes
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Alnylam Pharmaceuticals
PR-M05-21-003May 05, 2021
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
Genentech
PA1285Sep 18, 2020
Clinical Trials
Soligenix Announces Positive Recommendation on its Phase 3 Clinical Trial for the Treatment of Oral Mucositis
Soligenix, Inc.
PR-M09-19-NI-007Sep 04, 2019
Phase III
GSK Announces Positive Headline Results in Phase 3 PRIMA Study of ZEJULA (niraparib) For Patients with Ovarian Cancer
GSK
PR-M07-19-NI-039Jul 16, 2019
Phase III
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
Nice Insight
PR-M07-19-NI-023Jul 10, 2019
Phase III
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
Inovio Pharmaceuticals, Inc.
PR-M05-19-NI-022May 08, 2019
Drug Development
New NASH Treatment Achieves Positive Phase III Results
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M02-19-NI-018Feb 21, 2019
Clinical Trials
Avapritinib Receives Phase III Clinical Trial Approval for GIST in China
CStone Pharmaceuticals
PR-M02-19-NI-038Feb 19, 2019
Phase III
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study: Advances in Sleep and Circadian Science
Eisai
PR-M02-19-NI-010Feb 06, 2019
Oncology
Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer
Innovent Biologics, Inc.
PR-M01-19-NI-012Jan 08, 2019
Clinical Trial
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
Prometic
PR-M12-18-NI-028Dec 10, 2018
Biosimilars
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
Amgen
PR-M06-18-NI-100Jun 29, 2018
Clinical Trials
Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Pfizer
PR-M04-18-NI-51Apr 16, 2018
Clinical Trials
First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer
On Target Laboratories, Inc.
PR-M04-18-NI-33Apr 10, 2018
Clinical Trials
Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy
Pfizer
PR-M04-18-NI-006Apr 03, 2018
Clinical Trials
Aimmune’s AR101 Meets Phase 3 Endpoints
Guy Tiene
Nice Insight
PAO-M02-18-NI-020Feb 22, 2018
Oncology
Device Plus Drug Approved for Bladder Cancer Detection
Nigel Walker
Nice Insight
PAO-M02-18-NI-018Feb 21, 2018
Phase 3
Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Eli Lilly and Company
PR-M02-18-NI-61Feb 16, 2018
Oncology
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
Amgen
PR-M01-18-NI-074Jan 24, 2018